Therapeutic Study of ONO-4819CD for Ulcerative Colitis

A Randomized, Placebo-Controlled Trial of ONO-4819CD for Treatment of Mild to Moderate Ulcerative Colitis.

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00296556

Enrollment

Registered

2006-02-27

Start date

2006-02-28

Completion date

2008-03-31

Last updated

2009-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Keywords

Ulcerative colitis, EP4 agonist, PGE2

Brief summary

The purpose of this study is to investigate whether ONO-4819CD is safe and effective in the treatment of mild to moderate ulcerative colitis.

Detailed description

Ulcerative colitis is a relapsing disease of unknown cause characterized by bloody diarrhea. Therapy usually involves 5-aminosalicylates, corticosteroids and immunosuppressants. However, steroid resistance and dependency can become problematic. Immunosuppressive drugs, such as azathioprine, are beneficial but may have serious side effects. Therefore, new therapeutic approach is needed. Prostaglandin E2 is one of the prostanoids, which is involved with innate immunity. PGE2 induces oral tolerance to specific antigen in the small intestine and downregulates the production and release of proinflammatory cytokines by macrophages and neutrophils. Accordingly, PGE2 is considered to be the mediator of mucosal protection. Recently, it was elucidated that disruption of EP4 gene, which is one of PGE receptors, caused severe colitis in mice. Moreover, EP4-selective agonist (AE1-734) was also revealed to ameliorate severe dextran sodium sulfate-induced colitis in mice. We therefore examined the effects of 2 weeks intravenous EP4-selective agonist therapy for patients with mild to moderate ulcerative colitis.

Interventions

DRUGRivenprost (drug)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Clinical diagnosis of ulcerative colitis 2. Mild to moderate ulcerative colitis refractory to 5-aminosalicylates therapy. 3. 20 years and above 4. Must obtain written informed consent

Exclusion criteria

1. Corticosteroids therapy within two weeks before enrollment 2. Immunosuppressive therapy within three months before enrollment 3. Leukocytapheresis therapy within one month before enrollment 4. Blood transfusion within two weeks before enrollment 5. Impaired renal function 6. Impaired hepatic function 7. Uncontrolled hypertension/hypotension 8. Uncontrolled arrhythmia 9. Impaired cardiac function 10. Cancer 11. Uncontrolled diabetes 12. Interstitial pneumonia 13. Glaucoma 14. History of colon resection 15. Infectious diseases needing medical treatments 16. Drug allergy 17. Pregnancy

Design outcomes

Primary

Measure	Time frame
Remission evaluated by DAI scores at 14 and 28 days	—

Secondary

Measure	Time frame
Improvement by DAI scores; Change in DAI scores; CAI scores at 3, 7, 14 and 28 days; Colonoscopic and histopathological scores at 14 and 28 days; Clinical severity and symptom scores at 7, 14 and 28 days; Cytokines at 7, 14 and 28 days; Adverse effects.	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026